ClinicalTrials.gg
RecruitingNCT06317805TripleTREUpdated Oct 29, 2026

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

A Phase 4 interventional study of Generic treprostinil sodium + Standard of Care (Double Oral) and Standard of Care - Double Oral in Pulmonary Arterial Hypertension, sponsored by AOP Orphan Pharmaceuticals AG. Recruiting at 28 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by AOP Orphan Pharmaceuticals AG · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Oct 29, 2026First sites in Argentina and UruguayEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Pulmonary Arterial Hypertension with a site in Argentina — 7 open to participants now, 11 under way, 7 of them phase 3. Pulmonary Arterial Hypertension · Argentina.

Planned enrollment
32nd of 40
110 · median 291
Started
2023
with 3 others
Phase 4
3 of 42
1 open now
Primary completion
2027-06
later than 4 of 10 live
Registered
36th of 42
by date

Among the 42 studies in Pulmonary Arterial Hypertension with a site in Argentina, this one is the 32nd largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 4, reaches primary completion later than 4 of the 10 other live ones, and was the 36th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 42 studies in Pulmonary Arterial Hypertension with a site in Argentina are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Pulmonary Arterial Hypertension with a site in Argentina, or all of them as a file.
02

Study summary

TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy (oral ERA + oral PDE-5i) in pulmonary arterial hypertension (PAH) patients (group I) with intermediate-high risk or patients with intermediate-low risk with severe hemodynamic impairment at baseline in a prospective, randomized, unblinded setting with scope of increasing evidence for optimization of therapy concepts in PAH.

The effect of initial triple combination therapy vs initial double oral therapy (standard of care (SoC)) will be measured by primary endpoint: (non)response to the assigned treatment.

Read the detailed description

TripleTRE is prospective, randomized, two-arm, open-label, low-interventional, phase IV, multi-centre clinical trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy (standard of care (SoC)) by proportion of patients achieving low risk status according to the simplified four-strata risk-assessment tool from week 24 up to 48 weeks in 110 (55/group) treatment-naïve adult intermediate-high risk or intermediate-low risk participants with severe hemodynamic impairment with pulmonary arterial hypertension (PAH) (group I). Severe hemodynamic impairment is defined in current European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines as at least one of following conditions: mean right atrial pressure (RAP) ≥ 20 mmHg, cardiac index (CI) \< 2.0 L/min, stroke volume index (SVI) \< 31 mL/m2 and/or pulmonary vascular resistance (PVR) ≥ 12 WU. Risk status will be assessed with the simplified four-strata risk-assessment tool as per ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2022).

TripleTRE will be performed in adult participants with a confirmed diagnosis of idiopathic PAH (IPAH), hereditary PAH (HPAH), drug and toxin-induced PAH (DPAH), PAH associated with Connective Tissue Disease (PAH-CTD) and PAH with corrected congenital heart disease (PAH-CHD).

Participants will be randomized to one of the two treatment arms in 1:1 ratio. All patients will start with double oral background medication (endothelin receptor antagonist (ERA) and phosphodiesterase type-5 inhibitor (PDE-5i)). Choice of double oral drug combination underline the discretion of the investigator and applicable treatment guidelines. In both treatment arms all drugs (i.e., background medication in double oral group, background medication and parenteral treprostinil in initial triple group) will be initiated within 3 weeks after randomization. Patients randomized to treprostinil arm will receive training on infusion pump and medication after that investigational medicinal product will be handed out. All patients will be handed out diaries for documentation of treprostinil dose and used vials.

Primary objective of TripleTRE is to investigate the effect of initial triple combination therapy compared to initial double oral therapy on risk status. The effect of initial triple combination therapy vs initial double oral therapy (SoC) will be measured by primary endpoint: (non)response to the assigned treatment, whereas therapy responders/non-responders are defined as:

  1. Therapy-responder: achievement of low-risk status between week 24 and week 48
  2. Therapy-non-responder:

    1. pulmonary hypertension (PH) related deterioration to high-risk status, lung transplantation or death between week 12 and week 48 and/or
    2. additional medication or change of initial PH specific medication due to unsatisfactory efficacy between week 12 and week 48 and/or
    3. low risk status not achieved up to week 48

Risk status is assessed with the simplified four-strata risk-assessment tool as per ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2022).

Commonly used variables such as hemodynamics, echocardiogram (ECHO) and time to clinical worsening will be evaluated as secondary endpoints. In addition, the emPHasis-10 questionnaire will be used as disease specific and validated patient-reported outcome tool for PAH patients. The European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) will be used as general patient-reported outcome tool independent from disease.

TripleTRE trial is organized as a low-intervention trial consistent with definition in Clinical Trial Regulation (Regulation (EU) No 536/2014). Participants will not undergo any invasive examinations or laboratory evaluations, diagnostic or monitoring procedures specifically for the purposes of this trial that would expose them to increased risk compared to standard of care. Trial-related procedures as well as the frequency of assessments are in alignment with ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2022) and are not expected to pose additional risks to patients.

Planned trial duration per patient is minimum 12 weeks and maximum 48 weeks with up to 10 visits depending on achievement of therapy responder (i.e., low risk status) or therapy non-responder status. The visits 2 and 3 can be performed on phone. Other visits will be performed on-site. The trial will only be conducted in countries where ERA and PDE-5i treatments are standard of care and treprostinil is available to patients. At the end of trial, patients will be treated according to routine medical care at the PH expert centers receiving locally reimbursed medications. Approximately 10 countries and 20 sites are planed.

Statistical considerations:

The complete statistical analysis plan (SAP) was finalized before first patient in (FPI) in meaning of first act of recruitment. A one-sided Boschloo exact test at 2.5% significance level will be used to test the following primary hypothesis:

H0: Proportion of patients achieving low risk status (therapy responders) between week 24 and week 48 after baseline in the initial Triple treatment group is less or equal to the proportion of patients achieving low risk status between week 24 and week 48 after baseline in the initial Double oral treatment group.

The null hypothesis will be rejected if the 97.5% CI of the difference of proportions of therapy responders (triple minus double) is greater than 0.

To account for the variable time on treatment of therapy responders, a secondary sensitivity analysis will be performed by comparing the median time to the achievement of the low-risk status between the treatment groups.

Further sensitivity and subgroup analyses are defined in detail the statistical analysis plan (SAP) including the handling of missing values.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • intermediate-high risk
  • intermediate-low risk with severe hemodynamic impairment
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Signed prior to any trial-mandated procedure
  2. Male or female ≥ 18 and ≤ 75 years of age
  3. Newly diagnosed treatment-naïve PAH patients (PH group I) defined as receiving no specific therapy to treat PAH
  4. Intermediate-high risk patients or intermediate-low risk with severe haemodynamic impairment fulfilling at least one of the following criteria: CI \< 2.0 L/min, SVI \< 31 mL/m², PVR ≥ 10 WU or SvO2 \< 60 %; rated according to the simplified four-strata risk-assessment tool
  5. Right Heart Catheterization (RHC) meeting all the following criteria:

    • Mean pulmonary arterial pressure (mPAP) > 20 mmHg
    • Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
    • PVR > 2 Wood Units
  6. Women of must not be pregnant or lactating, must perform regular pregnancy tests, if sexually active, agrees to continue to use reliable method(s) of until study completion

Exclusion Criteria:

Inclusion criteria at randomization:

  1. Signed informed consent prior to any trial-mandated procedure
  2. Male or female ≥ 18 and ≤ 75 years of age
  3. Newly diagnosed treatment-naïve PAH patients (PH group I) defined as receiving no specific therapy to treat PAH
  4. Intermediate-high risk patients or intermediate-low risk with severe haemodynamic impairment fulfilling at least one of the following criteria: CI \< 2.0 L/min, SVI \< 31 mL/m², PVR ≥ 10 WU or SvO2 \< 60 %; rated according to the simplified four-strata risk-assessment tool
  5. Right Heart Catheterization (RHC) meeting all the following criteria:

    • Mean pulmonary arterial pressure (mPAP) > 20 mmHg
    • Pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg
    • PVR > 2 Wood Units
  6. Women of childbearing potential must not be pregnant or lactating, must perform regular pregnancy tests, and agree to continue to use a highly effective birth control method until study completion

Exclusion criteria at randomization:

  1. PAH patients (PH Group I) belonging to one of the following subgroups:

    • Schistosomiasis
    • infection
    • Portal hypertension
    • Diffuse systemic sclerosis with organ involvement that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy
    • Uncorrected congenital heart disease including uncorrected systemic-to-pulmonary shunts
  2. Patients not able to walk due to concomitant disease
  3. Patients responding to vasoreactivity testing with calcium channel blockers (CCB)
  4. Post-capillary PH and left heart disease
  5. Known or suspected pulmonary veno-occlusive disease (PVOD)
  6. Any PH due to lung disease
  7. Any disorder of the respiratory system or suspicion of PVOD expressed by DLCO \<40% and a noticeable imaging result (i.e. chest CT, CT pulmonary angiography) and plethysmography or forced spirometry below lower limit of normal
  8. (BMI) > 40 (kg/m2)
  9. History of restrictive, constrictive or congestive cardiomyopathy, atrial septostomy, any symptomatic coronary disease events within 6 months, severe uncontrolled arterial hypertension, acutely decompensated heart failure and myocardial infarction within 90 days, significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease, chronic systemic hypotension, unstable angina pectoris, permanent/persistent atrial fibrillation and/or need for pacemaker
  10. Patients with acute anaemia with (Hb) values \<11 g/dL
  11. Cerebrovascular accident within 3 months
  12. Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total ≥ 3× (ULN) or by (AST) ≥5x ULN or alkaline phosphatase ≥5x ULN or Class C
  13. Documented renal insufficiency with \<30 ml/min
  14. Patients with untreated sleep apnoea
  15. Patient with other cardiovascular, liver, renal, haematologic, gastrointestinal (including active gastrointestinal ulcer), immunologic, endocrine (e.g., uncontrolled diabetes), metabolic, or central nervous system disease and acute bleeding and injuries (e.g., intracranial haemorrhage) that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy or significantly limit the lifespan (\< 12 months)
  16. Patients with major surgery in the last 12 months that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy
  17. Treatment of a CYP2C8 enzyme inducer (e.g., rifampicin) ≤ 28 days and/or treatment of a cytochrome P450 (CYP)2C8 enzyme inhibitor (e.g., gemfibrozil) ≤ 28 days
  18. Treatment with another drug (planned, or taken ≤ 12 weeks)
  19. to any of the trial treatments or any of their formulations
  20. Pregnancy, breastfeeding, or intention to become pregnant during the trial
  21. Any other significant disease or disorder which, in the opinion of the investigator, may put the patients at risk when participating in the trial
  22. Any factor or condition likely to affect protocol compliance of the patient, as judged by the investigator
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Initial triple therapy

    Assigned treatment: double oral (background therapy consisting of 1 endothelin receptor antagonist ERA and 1 phosphodiesterase type-5 inhibitor PDE-5i) with subcutaneous (SC)/intravenous (IV) treprostinil on top

    Drug: Generic treprostinil sodium + Standard of Care (Double Oral) · Drug: Standard of Care - Double Oral

  • Active comparator
    • Initial double therapy

    double oral (background therapy consisting of 1 endothelin receptor antagonist ERA and 1 phosphodiesterase type-5 inhibitor PDE-5i)

Interventions

  • DrugGeneric treprostinil sodium + Standard of Care (Double Oral)

    Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.

    Also known as: Trisuva, Tresuvi, Treposa, Treprostinil Orpha-Devel, Treprostinil Amomed, Treprostinil OrPha, Treposuvi

  • DrugStandard of Care - Double Oral

    All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)

06

What researchers measure

Primary outcomes

  1. Patients achieving (non-)response status to the assigned treatment in terms of achievement of low-risk status

    1. Therapy-responder: achievement of low-risk status between week 24 and week 48 2. Therapy-non-responder: 1. PH related deterioration to high-risk status, lung transplantation or death between week 12 and week 48 and/or 2. additional medication or change of initial PH specific medication due to unsatisfactory efficacy between week 12 and week 48 and/or 3. low risk status not achieved up to week 48 Risk status is assessed with the simplified four-strata risk-assessment tool as per PH guidelines.

    Time frame: between week 12 and week 48 from baseline (BL)

Secondary outcomes

  1. Change in hemodynamic parameters by means of right heart catheterization (RHC) - PVR

    Pulmonary Vascular Resistance (PVR) measured in WU

    Time frame: at week 24 from baseline (BL)

  2. Change in hemodynamic parameters by means of right heart catheterization (RHC) - mPAP

    Mean pulmonary arterial pressure (mPAP) measured in mmHg

    Time frame: at week 24 from baseline (BL)

  3. Change in hemodynamic parameters by means of right heart catheterization (RHC) - mRAP

    Mean right atrial pressure (mRAP) measured in mmHg

    Time frame: at week 24 from baseline (BL)

  4. Change in hemodynamic parameters by means of right heart catheterization (RHC) - CI

    Cardiac index (CI) measured in liters per minute per square meter

    Time frame: at week 24 from baseline (BL)

  5. Change in hemodynamic parameters by means of right heart catheterization (RHC) - CO

    Cardiac output (CO) measured in liters per minute

    Time frame: at week 24 from baseline (BL)

  6. Change in hemodynamic parameters by means of right heart catheterization (RHC) - RAP

    Right atrial pressure (RAP) measured in mmHg

    Time frame: at week 24 from baseline (BL)

  7. Change in right heart structure and function assessed by echocardiography - TAPSE/sPAP

    RV-PA coupling estimated by the ratio of tricuspid annular plane systolic excursion by pulmonary artery systolic pressure (TAPSE/sPAP)

    Time frame: at week 24 from baseline (BL)

  8. Change in right heart structure and function assessed by echocardiography - RVEDA

    RV end-diastolic area (RVEDA) measured in square centimeters

    Time frame: at week 24 from baseline (BL)

  9. Change in right heart structure and function assessed by echocardiography - RVESA

    RV end-systolic area (RVESA) measured in square centimeters

    Time frame: at week 24 from baseline (BL)

  10. Change in right heart structure and function assessed by echocardiography - RVFAC

    RV fractional area change (RVFAC) calculated in %

    Time frame: at week 24 from baseline (BL)

  11. Change in right heart structure and function assessed by echocardiography - RA

    Right Atrium (RA) area in square centimeters

    Time frame: at week 24 from baseline (BL)

  12. Change in right heart structure and function assessed by echocardiography - Pericardial effusion

    Pericardial effusion assessment will be done and rated as yes/no

    Time frame: at week 24 from baseline (BL)

  13. Time to achievement of low-risk status

    Time from baseline to achievement of low-risk status assessed by the simplified four-strata risk-assessment tool

    Time frame: time from baseline (BL) up to week 48

  14. Rate of change of risk status

    by means of the simplified four-strata risk-assessment tool categorizing patients in low (1), intermediate-low (2), intermediate-high (3) and high risk (4) based on the outcome in WHO FC class assessment, 6MWD and BNP/NT-proBNP

    Time frame: between baseline and week 48

  15. Change in the number of low-risk criteria based on the French PH Network Registry (FPHR) risk assessment tool

    Time frame: between baseline and week 24

  16. Change in REVEAL 2.0 risk score

    REVEAL Registry Risk Score 2.0 for Pulmonary Arterial Hypertension (PAH) predicts survival in patients with pulmonary arterial hypertension. It classifies patients in 3 risk groups: * Low: REVEAL score ≤6 meaning a predicted 1-year survival of ≥94% * Intermediate: REVEAL score 7-8 meaning a predicted 1-year survival of 70% to \<94% * High: REVEAL score ≥9 meaning a predicted 1-year survival of \<70%

    Time frame: between baseline and week 24

  17. Rate of change in WHO-FC

    Time frame: between baseline and week 48

  18. Rate of change in 6MWD

    Time frame: between baseline and week 48

  19. Rate of change in NT-proBNP/BNP levels

    Time frame: between baseline and week 48

  20. Total number of clinical worsening(s)

    where clinical worsening is defined as: * PAH related death (including all deaths where PAH cannot be excluded as cause) and lung transplantation due to PAH * PH-related hospitalization * Post baseline (screening visit) decrease in 6MWD by 15% * Post baseline (screening visit) worsening of WHO FC

    Time frame: between baseline and week 48

  21. Overall and transplant free survival

    Time frame: between baseline and week 48

  22. Rate of change in quality of life - emPHasis-10

    Emphasis meaning something of special importance or significance. Please translate using the most appropriate term. The PH in emPHasis represents the condition Pulmonary Hypertension. The number 10 refers to the number of items in the questionnaire. This questionnaire is designed to determine how Pulmonary Hypertension (PH) affects patient's life. It refers to how PH affects or the impact that PH has on the patient's life.

    Time frame: between baseline and week 48

  23. Rate of change in quality of life - EQ-5D-5L

    The EQ-5D-5L questionnaire consists of 2 parts - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. It should be noted that the numerals 1-5 have no arithmetic properties and should not be used as a cardinal score.

    Time frame: between baseline and week 48

Other outcomes

  1. Safety outcomes:

    1. Number of Adverse events (AE) and Adverse reactions (ADR) 2. Number of Serious Adverse events (SAE) and Serious Adverse Drug Reactions (SADR) 3. Number of Suspected unexpected serious adverse reactions (SUSAR)

    Time frame: between baseline and week 48

07

Study locations

3 of 28 sites recruiting
  • Instituto Neumonológico del Sur (INEUS)
    Bahía Blanca, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Gallego de Buenos Aires
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fundación Favaloro
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Británico de Buenos Aires
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Italiano de Buenos Aires (HIBA)
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Ramos Mejia
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sanatorio Mitre de Buenos Aires
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Médico Capital
    La Plata, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ordensklinikum Linz
    Linz, Austria
    Recruiting
  • Medical University Vienna
    Vienna, Austria
    Recruiting
  • Fakultní Nemocnice Olomouc
    Olomouc, Czechia
    Not yet recruiting
    • Jan Přeček · Contactjan.precek@fnol.cz · +420588445102
    • Jan Přeček · Principal investigator
  • Všeobecná fakultní nemocnice v Praze
    Prague, Czechia
    Not yet recruiting
    • Pavel Jansa · Contactpavel.jansa@vfn.cz · +420224962629
    • Pavel Jansa · Principal investigator
  • Hôpital Bicêtre-- Assistance Publique Hopitaux de Paris
    Paris, France
    Not yet recruiting
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, France
    Not yet recruiting
  • DRK Kliniken Berlin Westend
    Berlin, Germany
    Not yet recruiting
  • University Hospital Carl Gustav Carus of Technical University Dresden
    Dresden, Germany
    Not yet recruiting
  • Universitätsmedizin Greifswald
    Greifswald, Germany
    Not yet recruiting
  • Gottsegen National Cardiovascular lnstitute
    Budapest, Hungary
    Not yet recruiting
    • Olga Hajnalka Balint · Contacttitkarsag@kardio.hu · +3612152139
    • Olga Hajnalka Balint · Principal investigator
  • Medical University of Szeged
    Szeged, Hungary
    Not yet recruiting
  • Sapienza University of Rome
    Rome, Italy
    Recruiting
  • John Paul II Hospital Krakow
    Krakow, Poland
    Not yet recruiting
    • Grzegorz Kopeć · Contact+48126143399
    • Grzegorz Kopeć · Principal investigator
  • Fryderyk Chopin Hospital in European Health Centre Otwock
    Otwock, Poland
    Not yet recruiting
  • Centro Hospitalar Lisboa Norte - Santa Maria University Hospital
    Lisbon, Portugal
    Not yet recruiting
  • Emergency Institute for Cardiovascular Diseases Prof. Dr. C.C.Iliescu
    Bucharest, Romania
    Not yet recruiting
    • Ioan Mircea Coman · Contact+40213175222
    • Ioan Mircea Coman · Principal investigator
  • Emergency Clinical County Hospital of Targu Mures
    Târgu Mureş, Romania
    Not yet recruiting
    • Ioan Tilea · Contactioan.tilea@umfst.ro · +40265215551
    • Ioan Tilea · Principal investigator
  • Hospital Clinic of Barcelona
    Barcelona, Spain
    Not yet recruiting
    • Isabel Blanco Vich · Contactiblanco2@clinic.cat · +34932275779
    • Isabel Blanco Vich · Principal investigator
  • Hospital Ramon y Cajal
    Madrid, Spain
    Not yet recruiting
    • Jose Andres Tenes Mayen · Contactjtenes@salud.madrid.org · +34913368263
    • Jose Andres Tenes Mayen · Principal investigator
  • Hospital Maciel
    Montevideo, Uruguay
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Jun 2027, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 19, 2024
StartActual
Dec 6, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added, 4 sites removed — first sites in Argentina and Uruguay
Show 13 added (8 Argentina, 1 Czechia, 1 Poland, 1 Portugal, 1 Romania, 1 Uruguay)
  • Instituto Neumonológico del Sur (INEUS) · Bahía Blanca, Argentina
  • Centro Gallego de Buenos Aires · Buenos Aires, Argentina
  • Fundación Favaloro · Buenos Aires, Argentina
  • Hospital Británico de Buenos Aires · Buenos Aires, Argentina
  • Hospital Italiano de Buenos Aires (HIBA) · Buenos Aires, Argentina
  • Hospital Ramos Mejia · Buenos Aires, Argentina
  • Sanatorio Mitre de Buenos Aires · Buenos Aires, Argentina
  • Centro Médico Capital · La Plata, Argentina
  • Všeobecná fakultní nemocnice v Praze · Prague, Czechia
  • John Paul II Hospital Krakow · Krakow, Poland
  • Centro Hospitalar Lisboa Norte - Santa Maria University Hospital · Lisbon, Portugal
  • Emergency Clinical County Hospital of Targu Mures · Târgu Mureş, Romania
  • Hospital Maciel · Montevideo, Uruguay
Show 4 removed
  • Všeobecná fakultní nemocnice v Praze · Praha, Czechia
  • John Paul II Hospital Krakow · Kraków, Poland
  • Centro Hospitalar Lisboa Norte - Santa Maria University Hospital · Lisboa, Portugal
  • Emergency Clinical County Hospital of Targu Mures · Târgu-Mureş, Romania
Oct 29, 2026
Eligibility
Maximum age 70 Years→75 Years; 6 inclusion criteria removed; 8 exclusion criteria removed; 10 criteria edited, 19 added
What changed in the criteria
  • AddedInclusion Criteria:
  • EditedMale or female ≥ 18 and ≤ 7075 years of age
  • AddedNewly diagnosed treatment-naïve PAH patients (PH group I) defined as receiving no specific therapy to treat PAH
  • AddedIntermediate-high risk patients or intermediate-low risk with severe haemodynamic impairment fulfilling at least one of the following criteria: CI < 2.0 L/min, SVI < 31 mL/m², PVR ≥ 10 WU or SvO2 < 60 %; rated according to the simplified four-strata risk-assessment tool
  • AddedExclusion Criteria:
  • AddedInclusion criteria at randomization:
  • AddedSigned informed consent prior to any trial-mandated procedure
  • AddedMale or female ≥ 18 and ≤ 75 years of age
  • AddedNewly diagnosed treatment-naïve PAH patients (PH group I) defined as receiving no specific therapy to treat PAH
  • AddedIntermediate-high risk patients or intermediate-low risk with severe haemodynamic impairment fulfilling at least one of the following criteria: CI < 2.0 L/min, SVI < 31 mL/m², PVR ≥ 10 WU or SvO2 < 60 %; rated according to the simplified four-strata risk-assessment tool
  • AddedRight Heart Catheterization (RHC) meeting all the following criteria:
  • AddedMean pulmonary arterial pressure (mPAP) > 20 mmHg
  • AddedPulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg
  • AddedPVR > 2 Wood Units
  • AddedWomen of childbearing potential must not be pregnant or lactating, must perform regular pregnancy tests, and agree to continue to use a highly effective birth control method until study completion
  • AddedExclusion criteria at randomization:
  • EditedPAH patients (groupPH Group I) belonging to one of the following subgroups:
  • AddedDiffuse systemic sclerosis with organ involvement that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy
  • AddedPatients not able to walk due to concomitant disease
  • AddedAny disorder of the respiratory system or suspicion of PVOD expressed by DLCO <40% and a noticeable imaging result (i.e. chest CT, CT pulmonary angiography) and plethysmography or forced spirometry below lower limit of normal
  • EditedBody mass index (BMI) > 3540 (kg/m2)
  • EditedHistory of restrictive, constrictive or congestive cardiomyopathy, atrial septostomy, any symptomatic coronary disease events within 6 months, severe uncontrolled arterial hypertension, acutely decompensated heart failure and myocardial infarction within 3090 days, significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease, chronic systemic hypotension, unstable angina pectoris, permanent/persistent atrial fibrillation and/or need for pacemaker
  • EditedPatients with acute anemiaanaemia with hemoglobinhaemoglobin (Hb) values <11g11 g/dL
  • EditedDocumented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin >≥ 3× upper limit of the normal range (ULN) accompaniedor by aspartate aminotransferase (AST) >≥5x ULN and/or alkaline phosphatase ≥5x ULN or Child-Pugh Class C
  • EditedDocumented renal insufficiency with Glomerular Filtration Rate (GFR) <30 ml/min
  • EditedPatients with untreated sleep apneaapnoea
  • EditedPatient with other cardiovascular, liver, renal, hematologichaematologic, gastrointestinal (including active gastrointestinal ulcer), immunologic, endocrine (e.g., uncontrolled diabetes), metabolic, or central nervous system disease and acute bleeding and injuries (e.g., intracranial hemorrhagehaemorrhage) that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy or significantly limit the lifespan (< 12 months)
  • AddedPatients with major surgery in the last 12 months that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy
  • EditedTreatment of a a cytochrome P450 (CYP)2C8CYP2C8 enzyme inducer (e.g., rifampicin) ≤ 28 days and/or treatment of a CYP2C8cytochrome P450 (CYP)2C8 enzyme inhibitor (e.g., gemfibrozil) ≤ 28 days
Inclusion criteria
  • RemovedSymptomatic treatment-naïve PAH patients (group I) with confirmed diagnosis of one of the following subgroups:
  • Removedidiopathic pulmonary arterial hypertension (IPAH)
  • Removedhereditary pulmonary arterial hypertension (HPAH)
  • RemovedDrug and toxin-induced pulmonary arterial hypertension (DPAH)
  • RemovedPAH associated with Connective Tissue Disease
  • RemovedPAH with corrected congenital heart disease 4. Intermediate-high risk patients rated acc. the simplified four-strata risk-assessment tool or intermediate-low risk with severe hemodynamic impairment as defined in current PH guidelines i.e., mean right atrial pressure (RAP) ≥ 20 mmHg, cardiac index (CI) < 2.0 L/min, stroke volume index (SVI) < 31 mL/m2 and/or pulmonary vascular resistance (PVR) ≥ 12 WU
Exclusion criteria
  • RemovedDiffuse systemic sclerosis
  • RemovedAny PAH-specific drug therapy in the past 3 months
  • RemovedAny disorder of the respiratory system expressed by Diffusing Capacity of Lung for Carbon Monoxide (DLCO) <40% and a noticeable imaging result (e.g., CT) and (Total Lung Capacity) TLC <60% and (Forced Expiratory Volume) FEV1 <70% by plethysmography (a pulmonary function test)
  • RemovedPatients with need of ambulatory or long-term oxygen therapy
  • RemovedElectrocardiogram (ECG) with Fridericia's corrected QT interval (QTcF) > 480 msec at screening

…and 3 more changes, on the record history on ClinicalTrials.gov ↗

Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    13 sites added, 4 sites removed — first sites in Argentina and Uruguay
    Show 13 added (8 Argentina, 1 Czechia, 1 Poland, 1 Portugal, 1 Romania, 1 Uruguay)
    • Instituto Neumonológico del Sur (INEUS) · Bahía Blanca, Argentina
    • Centro Gallego de Buenos Aires · Buenos Aires, Argentina
    • Fundación Favaloro · Buenos Aires, Argentina
    • Hospital Británico de Buenos Aires · Buenos Aires, Argentina
    • Hospital Italiano de Buenos Aires (HIBA) · Buenos Aires, Argentina
    • Hospital Ramos Mejia · Buenos Aires, Argentina
    • Sanatorio Mitre de Buenos Aires · Buenos Aires, Argentina
    • Centro Médico Capital · La Plata, Argentina
    • Všeobecná fakultní nemocnice v Praze · Prague, Czechia
    • John Paul II Hospital Krakow · Krakow, Poland
    • Centro Hospitalar Lisboa Norte - Santa Maria University Hospital · Lisbon, Portugal
    • Emergency Clinical County Hospital of Targu Mures · Târgu Mureş, Romania
    • Hospital Maciel · Montevideo, Uruguay
    Show 4 removed
    • Všeobecná fakultní nemocnice v Praze · Praha, Czechia
    • John Paul II Hospital Krakow · Kraków, Poland
    • Centro Hospitalar Lisboa Norte - Santa Maria University Hospital · Lisboa, Portugal
    • Emergency Clinical County Hospital of Targu Mures · Târgu-Mureş, Romania
    Eligibility Maximum age 70 Years→75 Years; 6 inclusion criteria removed; 8 exclusion criteria removed; 10 criteria edited, 19 added
    What changed in the criteria
    • AddedInclusion Criteria:
    • EditedMale or female ≥ 18 and ≤ 7075 years of age
    • AddedNewly diagnosed treatment-naïve PAH patients (PH group I) defined as receiving no specific therapy to treat PAH
    • AddedIntermediate-high risk patients or intermediate-low risk with severe haemodynamic impairment fulfilling at least one of the following criteria: CI < 2.0 L/min, SVI < 31 mL/m², PVR ≥ 10 WU or SvO2 < 60 %; rated according to the simplified four-strata risk-assessment tool
    • AddedExclusion Criteria:
    • AddedInclusion criteria at randomization:
    • AddedSigned informed consent prior to any trial-mandated procedure
    • AddedMale or female ≥ 18 and ≤ 75 years of age
    • AddedNewly diagnosed treatment-naïve PAH patients (PH group I) defined as receiving no specific therapy to treat PAH
    • AddedIntermediate-high risk patients or intermediate-low risk with severe haemodynamic impairment fulfilling at least one of the following criteria: CI < 2.0 L/min, SVI < 31 mL/m², PVR ≥ 10 WU or SvO2 < 60 %; rated according to the simplified four-strata risk-assessment tool
    • AddedRight Heart Catheterization (RHC) meeting all the following criteria:
    • AddedMean pulmonary arterial pressure (mPAP) > 20 mmHg
    • AddedPulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg
    • AddedPVR > 2 Wood Units
    • AddedWomen of childbearing potential must not be pregnant or lactating, must perform regular pregnancy tests, and agree to continue to use a highly effective birth control method until study completion
    • AddedExclusion criteria at randomization:
    • EditedPAH patients (groupPH Group I) belonging to one of the following subgroups:
    • AddedDiffuse systemic sclerosis with organ involvement that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy
    • AddedPatients not able to walk due to concomitant disease
    • AddedAny disorder of the respiratory system or suspicion of PVOD expressed by DLCO <40% and a noticeable imaging result (i.e. chest CT, CT pulmonary angiography) and plethysmography or forced spirometry below lower limit of normal
    • EditedBody mass index (BMI) > 3540 (kg/m2)
    • EditedHistory of restrictive, constrictive or congestive cardiomyopathy, atrial septostomy, any symptomatic coronary disease events within 6 months, severe uncontrolled arterial hypertension, acutely decompensated heart failure and myocardial infarction within 3090 days, significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease, chronic systemic hypotension, unstable angina pectoris, permanent/persistent atrial fibrillation and/or need for pacemaker
    • EditedPatients with acute anemiaanaemia with hemoglobinhaemoglobin (Hb) values <11g11 g/dL
    • EditedDocumented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin >≥ 3× upper limit of the normal range (ULN) accompaniedor by aspartate aminotransferase (AST) >≥5x ULN and/or alkaline phosphatase ≥5x ULN or Child-Pugh Class C
    • EditedDocumented renal insufficiency with Glomerular Filtration Rate (GFR) <30 ml/min
    • EditedPatients with untreated sleep apneaapnoea
    • EditedPatient with other cardiovascular, liver, renal, hematologichaematologic, gastrointestinal (including active gastrointestinal ulcer), immunologic, endocrine (e.g., uncontrolled diabetes), metabolic, or central nervous system disease and acute bleeding and injuries (e.g., intracranial hemorrhagehaemorrhage) that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy or significantly limit the lifespan (< 12 months)
    • AddedPatients with major surgery in the last 12 months that, in the opinion of the investigator, may adversely affect the safety of the patient and /or efficacy of the therapy
    • EditedTreatment of a a cytochrome P450 (CYP)2C8CYP2C8 enzyme inducer (e.g., rifampicin) ≤ 28 days and/or treatment of a CYP2C8cytochrome P450 (CYP)2C8 enzyme inhibitor (e.g., gemfibrozil) ≤ 28 days
    Inclusion criteria
    • RemovedSymptomatic treatment-naïve PAH patients (group I) with confirmed diagnosis of one of the following subgroups:
    • Removedidiopathic pulmonary arterial hypertension (IPAH)
    • Removedhereditary pulmonary arterial hypertension (HPAH)
    • RemovedDrug and toxin-induced pulmonary arterial hypertension (DPAH)
    • RemovedPAH associated with Connective Tissue Disease
    • RemovedPAH with corrected congenital heart disease 4. Intermediate-high risk patients rated acc. the simplified four-strata risk-assessment tool or intermediate-low risk with severe hemodynamic impairment as defined in current PH guidelines i.e., mean right atrial pressure (RAP) ≥ 20 mmHg, cardiac index (CI) < 2.0 L/min, stroke volume index (SVI) < 31 mL/m2 and/or pulmonary vascular resistance (PVR) ≥ 12 WU
    Exclusion criteria
    • RemovedDiffuse systemic sclerosis
    • RemovedAny PAH-specific drug therapy in the past 3 months
    • RemovedAny disorder of the respiratory system expressed by Diffusing Capacity of Lung for Carbon Monoxide (DLCO) <40% and a noticeable imaging result (e.g., CT) and (Total Lung Capacity) TLC <60% and (Forced Expiratory Volume) FEV1 <70% by plethysmography (a pulmonary function test)
    • RemovedPatients with need of ambulatory or long-term oxygen therapy
    • RemovedElectrocardiogram (ECG) with Fridericia's corrected QT interval (QTcF) > 480 msec at screening

    …and 3 more changes, on the record history on ClinicalTrials.gov ↗

    + 4 other changes: index terms, identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06317805
Lead sponsor
AOP Orphan Pharmaceuticals AG
Collaborators
ANOVA CRO s.r.o., PharmaLex Belgium, Aixial s.r.o., GCP-Service International Ltd. & Co. KG
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Dec 6, 2023
Primary completion
Jun 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Clinical Project Manager
Contact
tripletre@aoporphan.com
+43676 3464650

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion